Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers

OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimens have been used; due to concerns...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Jovana Y., Urban, Renata R., Liao, John B., Goff, Barbara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944014/
https://www.ncbi.nlm.nih.gov/pubmed/27329195
http://dx.doi.org/10.3802/jgo.2016.27.e47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944014/
https://www.ncbi.nlm.nih.gov/pubmed/27329195
http://dx.doi.org/10.3802/jgo.2016.27.e47

Ejemplares similares